{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:59:17Z","timestamp":1793397557137,"version":"4.5.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>To discuss different aspects of new bone formation in patients with spondyloarthritis based on emerging data from clinical trials, prospective cohort studies and translational laboratory investigations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>New bone formation potentially leading to ankylosis of the spine and sacroiliac joints remains an important concern for patients with axial spondyloarthritis. New therapeutic strategies, in particular targeting of interleukin-17, have emerged in addition to the antitumor necrosis factor drugs, but we still fail to fully understand the mechanisms of structural disease progression. A new paradigm is developing in which sustained and effective suppression of inflammation likely inhibits this structural disease progression. Biomechanical factors, in particular changes in bone microarchitecture in the vertebrae, and the need for core stability could provide a new framework to understand the relationship between bone remodeling and inflammation and to develop long-term strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>New bone formation leading to ankylosis remains a hallmark of axial spondyloarthritis and should be further investigated. The clinical data that progressively become available support the concept that effective and sustained therapy will be beneficial for the patients not only in short-term, but also in long-term outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000404","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T15:24:32Z","timestamp":1491060272000},"page":"287-292","source":"Crossref","is-referenced-by-count":30,"title":["Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis"],"prefix":"10.1097","volume":"29","author":[{"given":"Barbara","family":"Neerinckx","sequence":"first","affiliation":[{"name":"Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center"},{"name":"Division of Rheumatology, Department of Development and Regeneration, University Hospital Leuven, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Lories","sequence":"additional","affiliation":[{"name":"Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center"},{"name":"Division of Rheumatology, Department of Development and Regeneration, University Hospital Leuven, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/BOR.0000000000000254","article-title":"Microtrauma: no longer to be ignored in spondyloarthritis?","volume":"28","author":"Van Mechelen","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R6-20230828","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","article-title":"Pathophysiology of new bone formation and ankylosis in spondyloarthritis","volume":"38","author":"Lories","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.berh.2014.10.008","article-title":"Bone formation in axial spondyloarthritis","volume":"28","author":"Lories","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/art.34442","article-title":"Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation","volume":"64","author":"Maksymowych","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.080871","article-title":"The natural course of radiographic progression in ankylosing spondylitis: evidence for major individual variations in a large proportion of patients","volume":"36","author":"Baraliakos","year":"2009","journal-title":"J Rheumatol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","article-title":"The term \u2019nonradiographic axial spondyloarthritis\u2019 is much more important to classify than to diagnose patients with axial spondyloarthritis","volume":"75","author":"Deodhar","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-015-0535-y","article-title":"The ASAS criteria for axial spondyloarthritis: strengths, weaknesses, and proposals for a way forward","volume":"17","author":"van der Linden","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3899\/jrheum.160594","article-title":"Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-alpha inhibitors for up to 10 years","volume":"43","author":"Poddubnyy","year":"2016","journal-title":"J Rheumatol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.berh.2010.05.005","article-title":"Are current available therapies disease-modifying in spondyloarthritis?","volume":"24","author":"Lories","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R23-20230828","article-title":"Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with TNF-alpha inhibitors","author":"Maas","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11914-011-0058-z","article-title":"Osteoporosis: a paradox in ankylosing spondylitis","volume":"9","author":"Carter","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"R25-20230828","article-title":"Clinical risk factors for the presence and development of vertebral fractures in patients with ankylosing spondylitis","author":"Maas","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R26-20230828","article-title":"Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF-alpha inhibitors: facet joints vs. vertebral bodies","author":"Maas","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis: results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R29-20230828","first-page":"3","article-title":"Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab","volume":"67","author":"Baraliakos","year":"2015","journal-title":"Arthritis Rheum"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial Effects of NSAIDs on Radiographic Damage in Ankylosing Spondylitis","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2009.258","article-title":"Disease modification in ankylosing spondylitis","volume":"6","author":"Maksymowych","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/annrheumdis-2011-200859","article-title":"Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification","volume":"72","author":"Maksymowych","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/art.38792","article-title":"Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis","volume":"66","author":"Maksymowych","year":"2014","journal-title":"Arthritis Rheum"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/art.30393","article-title":"Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis","volume":"63","author":"Chiowchanwisawakit","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/annrheumdis-2015-208011","article-title":"MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis","volume":"75","author":"Machado","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","article-title":"Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R40-20230828","first-page":"744","article-title":"Which cells correspond to typical signals for fatty and inflammatory lesions seen on MRI in AS?","volume":"34","author":"Baraliakos","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI23738","article-title":"Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis","volume":"115","author":"Lories","year":"2005","journal-title":"J Clin Invest"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0070-2153(10)90008-2","article-title":"Vertebrate skeletogenesis","volume":"90","author":"Lefebvre","year":"2010","journal-title":"Curr Top Dev Biol"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2010.148262","article-title":"Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis","volume":"71","author":"Ruiz-Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"(Suppl S10)","key":"R46-20230828","first-page":"67","article-title":"IL-22 drives the proliferation and differentiation of human bone marrow mesenchymal stem cells (MSCs); a novel pathway that may contribute to aberrant new bone formation in human SPA and beyond","volume":"67","author":"El-Sherbiny","year":"2015","journal-title":"Arthritis Rheum"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bone.2016.01.010","article-title":"Proinflammatory T cells and IL-17 stimulate osteoblast differentiation","volume":"84","author":"Croes","year":"2016","journal-title":"Bone"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","article-title":"High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis","volume":"71","author":"Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.27231","article-title":"Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis","volume":"62","author":"Daoussis","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.7754\/Clin.Lab.2014.131119","article-title":"Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis","volume":"60","author":"Yucong","year":"2014","journal-title":"Clin Lab"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"e0134974","DOI":"10.1371\/journal.pone.0134974","article-title":"Increase in Dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR Cohort","volume":"10","author":"Nocturne","year":"2015","journal-title":"PLoS One"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T11:25:01Z","timestamp":1719141901000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000404","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}